lcmv gp33-41 acetate

LCMV gp33-41 acetate is a sequence of lymphocytic choriomeningitis virus which restricted by major histocompatibility complex class I H-2Db and presented to cytotoxic T lymphocytes.

Thymosin β4 (Tβ4) is a thymic hormone with multiple and different intracellular and extracellular activities affecting wound healing, inflammation, fibrosis and tissue regeneration.

α-helical CRF 9-41 acetate is a competitive antagonist of CRF2 (KB = 100 nM) and a partial agonist of CRF1 (EC50 = 140 nM).

Abaloparatide acetate is a parathyroid hormone receptor 1 PTHR1 analogue and an effective and selective activator of the PTHR1 signaling pathway.

IGF-I 30-41 acetate(82177-09-1 free base) (Insulin-like Growth Factor I (30-41) acetate) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I).

Dynorphin B (1-13) acetate acts as an agonist on opioid κ-receptor.

CRF (6-33) acetate is a corticotropin-releasing factor binding protein (CRFBP) inhibitor peptide; displaces CRF from CRFBP. Suppresses body weight gain and increases motor activity in obese rats in vivo.

Urotensin I acetate, a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC50s of 11.46, 9.36 and 9.85 for human CRF1, human CRF2 and rat CRF2α receptors in CHO cells, and Kis of 0.4, 1.8, and 5.7 nM for hCRF1, rCRF2α and mCRF2β receptors, respectively[1][2].

Orphanin FQ(1-11) acetate(178249-41-7 free base) is a peptide fragment containing amino acids 1-11 of Nociceptin. Orphanin FQ(1-11) acetate(178249-41-7 free base) is a potent agonist of the ORL1/KOR-3 receptor (Ki = 55 nM) and displays no affinity for opioid receptors, including μ, δ, κ1 and κ3 receptors (Ki >1000 nM). Orphanin FQ(1-11) acetate(178249-41-7 free base) displays analgesic properties in CD-1 mice.

OXA (17-33) acetate is a more potent agonist of orexin-1 receptor (OX1, EC50 = 8.29 nM)) over OX2 (EC50 = 187 nM).

LCMV gp33-41, the carboxyl-extended 11-aa-long peptide, is an H-2Db restricted epitope derived from the lymphocytic choriomeningitis virus (LCMV) glycoprotein gp 33 (residues 33 to 41) and is presented to cytotoxic T lymphocytes by MHC class I H-2Db molecules.

GP(33-41) TFA, a 9-amino-acid (aa) peptide, represents the optimal sequence of the lymphocytic choriomeningitis virus GP1 epitope, effectively upregulating H-2D b molecules on the RMA-S (Db Kb) cell surface with an SC50 value of 344 nM [1].

LCMV gp33-41 (TFA), an 11-amino-acid carboxyl-extended peptide, comprises a lymphocytic choriomeningitis virus sequence that is presented by MHC class I H-2Db molecules to cytotoxic T lymphocytes [1].

GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM. GP(33-41) Epitope is a strong agonist of CD8 T cells from P14 TCR-transgenic mice.

LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes[1].

LCMV GP (61-80) is a peptide fragment from LCMV glycoprotein (GP), corresponding to amino acids 61-80, and it can elicit a CD4+ T-cell response.